How a massive 1996 merger created one of the world's largest pharmaceutical giants
Novartis emerged from the historic union of Ciba-Geigy and Sandoz, two Swiss chemical titans. Since its inception, the company has aggressively reshaped its portfolio through complex acquisitions and divestments, evolving from a diversified chemical conglomerate into a focused healthcare powerhouse that navigates both scientific breakthroughs and significant legal controversies.
Formed in 1996, the merger between Ciba-Geigy and Sandoz was considered the largest corporate consolidation in history at the time. The new entity, named Novartis—derived from the Latin for 'new skills'—inherited a vast legacy. Ciba-Geigy itself was the result of a 1970 merger between two Basel-based firms, CIBA and Geigy, both of which had roots in the 19th-century dye industry. Sandoz, meanwhile, brought a history of pharmaceutical innovation, including the 1943 discovery of LSD's psychedelic effects by Albert Hofmann and Arthur Stoll.
Novartis spent the following decades refining its identity. It divested its agrochemical and genetically modified crop businesses in 2000 to form Syngenta, and later spun off its eye-care division, Alcon, in 2019. Throughout this period, the company pursued a strategy of rapid growth through acquisition, purchasing firms like Chiron in 2006 and The Medicines Company in 2019. These moves were designed to bolster its presence in specialized fields like oncology, gene therapy, and radiopharmaceuticals, while its Sandoz subsidiary continued to manage its generic drug portfolio.
The company's journey has not been without scrutiny. In the mid-1990s, the former Ciba-Geigy plant in Toms River, New Jersey, became a focal point for environmental concerns regarding cancer clusters, leading to its designation as a Superfund site. Furthermore, Novartis has faced significant legal challenges, including a 2020 settlement of $678 million regarding allegations of bribing physicians to prescribe its medications. Despite these hurdles, Novartis remains a dominant force in the global pharmaceutical market, consistently ranking among the top revenue-generating companies in the industry.
Source: Novartis
